RxDoctor Payments Data

Katie McAleer

Psychiatric/Mental Health · Huntingdon, PANPI 1669136578

Payments from drug & device makers

$2,329in general payments, 2019–2025

Across 112 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$269
  • Johnson & Johnson$196
  • AbbVie$148
  • Neurocrine Biosciences, Inc.$98
  • Axsome Therapeutics, Inc.$69
  • plus $318 from 10 others

What the payments were for

  • Food & beverage$2,31799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,329 in reported general payments places this provider in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,548
Medicare patients
31
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole30$64,641
CaplytaLumateperone Tosylate18$31,174
VraylarCariprazine Hcl11$12,527
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine181$5,469
Fluphenazine Hcl22$4,990
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine49$4,141
Aripiprazole28$3,875
Lurasidone Hcl45$2,844
Quetiapine Fumarate154$2,705
Trazodone Hcl211$2,477
Lamotrigine141$1,807
Carbamazepine ErCarbamazepine12$1,793
Gabapentin185$1,733
Divalproex Sodium ErDivalproex Sodium22$1,732
Oxcarbazepine39$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$269$64,64130 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,230$31,17418 claims
AbbVieVraylar$148$12,52711 claims
Almatica Pharma LLCSertraline Hcl$21$39096 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Huntingdon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →